市場調查報告書

全球黃斑部病變治療市場:成長,趨勢,及預測

Macular Degeneration Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 922004
出版日期 內容資訊 英文 113 Pages
商品交期: 2-3個工作天內
價格
全球黃斑部病變治療市場:成長,趨勢,及預測 Macular Degeneration Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 113 Pages
簡介

本報告提供全球黃斑部病變治療市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各類型·分期·給藥途徑·銷售管道·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 視網膜障礙的發生率上升
    • 老年人口的劇增
    • 研究開發投資的增加
  • 市場阻礙因素
    • 非適應症藥物的使用增加
    • AMD相關認識不足
  • 波特的五力分析

第5章 市場區隔

  • 各類型
    • 乾性老化相關的黃斑部病變
    • 老齡化性黃斑部病變
  • 各病期
    • 早期AMD
    • 中級AMD
    • 後期AMD
  • 各給藥途徑
    • 靜脈內途徑
    • 玻璃體內途徑
  • 各銷售管道
    • 門診病人手術中心
    • 醫院
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • F. Hoffmann-La Roche AG.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Bausch & Lomb Incorporated
    • Ophthotech Corporation
    • Neurotech Pharmaceuticals Inc.
    • Alimera Sciences Inc.
    • StemCells Inc.
    • Pfizer Inc.

第7章 市場機會及今後趨勢

目錄
Product Code: 67512

Market Overview

The macular degeneration treatment market was projected to grow with a CAGR of nearly 7.4% during the forecast period. The major factors attributing to the growth of the macular degeneration treatment market are, rise in the incidence of retinal disorders, increasing the geriatric population in the majority of the developing nations. According to the data published in the European Society of Retina Specialists (EURETINA) an estimated number of 33.6 million persons over the age of 60 years in Europe are currently affected by AMD. As per the statistics, the increasing number of individuals with retinal disorders is directly proportional to the market growth. Furthermore, the increasing research and development investments, rising approvals for the new drugs of the treatment are other major factors for the market growth. However, the increasing use of off-label drugs and lack of awareness regarding the disease are the major restraints to the growth of the market.

Scope of the Report

As per the scope of the report, macular degeneration is a retinal disorder affecting older people. Early stages of the disease, (early and intermediate AMD) are generally asymptomatic, which gradually make progress to late stages of the disease, which can cause severe visual loss. This report is segmented by type, by stage of the disease, by route of administration and by geography.

Key Market Trends

Wet AMD accounts for the Majority of Share in the Market

  • Wet macular degeneration is an initiation of atypical growth of blood vessels beneath the retina, these overgrown blood vessels drip blood which impedes clarity of central vision heading to macular degeneration.
  • The rising number of geriatric population all over the world is creating the high-level demand in wet macular degeneration market. According to the World Health Organization (WHO) report, the percentage of old people (above 60 years) is expected to become 21.1% by the year 2050. The total number of old age people all over the world is probable to reach 2 billion in 2050. All these statistics represent the high demand for the products for the treatment of wet macular degeneration globally in coming future. The technological advancements in the diagnosis of macular degeneration and appropriate reimbursement circumstances are driving the growth of the market.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall macular degeneration treatment market, throughout the forecast period. The market growth is because of more awareness and a greater proportion of total income spent on healthcare compared to other economies. According to BrightFocus Foundation, in 2016, 11 million people in the United States have certain forms of age-related macular degeneration. This number is estimated to reach nearly 22 million by 2050. The growing patient pool and the increasing geriatric population who are more prone to retinal diseases are the two major factors driving the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth.

Competitive Landscape

The macular degeneration treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bausch & Lomb Incorporated, IVERIC Bio, Neurotech Pharmaceuticals Inc., Alimera Sciences Inc., StemCells Inc., and Pfizer Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Incidence of Retinal Disorders
    • 4.2.2 Upsurge in Geriatric Population
    • 4.2.3 Increase in Research and Development Investments
  • 4.3 Market Restraints
    • 4.3.1 Increasing Use of Off-label Drugs
    • 4.3.2 Lack of Awareness regarding AMD
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Dry Age related macular degeneration
    • 5.1.2 Wet Age-related macular degeneration
  • 5.2 By Stage of Disease
    • 5.2.1 Early-stage AMD
    • 5.2.2 Intermediate AMD
    • 5.2.3 Late-stage AMD
  • 5.3 By Route of Administration
    • 5.3.1 Intravenous route
    • 5.3.2 Intravitreal route
  • 5.4 By Sales Channel
    • 5.4.1 Ambulatory surgical centers
    • 5.4.2 Hospitals
    • 5.4.3 Others
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 F. Hoffmann-La Roche AG.
    • 6.1.2 Novartis AG
    • 6.1.3 Regeneron Pharmaceuticals Inc.
    • 6.1.4 Bausch & Lomb Incorporated
    • 6.1.5 Ophthotech Corporation
    • 6.1.6 Neurotech Pharmaceuticals Inc.
    • 6.1.7 Alimera Sciences Inc.
    • 6.1.8 StemCells Inc.
    • 6.1.9 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS